Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 357

1.

Insights on Multiple Myeloma Treatment Strategies.

Mateos MV, Ludwig H, Bazarbachi A, Beksac M, Bladé J, Boccadoro M, Cavo M, Delforge M, Dimopoulos MA, Facon T, Geraldes C, Goldschmidt H, Hájek R, Hansson M, Jamroziak K, Leiba M, Masszi T, Mendeleeva L, O'Dwyer M, Plesner T, San-Miguel JF, Straka C, van de Donk NWCJ, Yong K, Zver S, Moreau P, Sonneveld P.

Hemasphere. 2018 Dec 27;3(1):e163. doi: 10.1097/HS9.0000000000000163. eCollection 2019 Feb. Review.

2.

Cytogenetic subclone formation and evolution in progressive smoldering multiple myeloma.

Merz M, Hielscher T, Schult D, Mai EK, Raab MS, Hillengass J, Seckinger A, Hose D, Granzow M, Jauch A, Goldschmidt H.

Leukemia. 2019 Nov 11. doi: 10.1038/s41375-019-0634-2. [Epub ahead of print] No abstract available.

PMID:
31712777
3.

Imaging Features of Multiple Myeloma Extramedullary Lesions in the Liver with 18F-FDG PET/CT, Contrast-Enhanced CT and MRI.

Papamichail D, Hog R, Goldschmidt H, Dimitrakopoulou-Strauss A.

Diagnostics (Basel). 2019 Nov 7;9(4). pii: E179. doi: 10.3390/diagnostics9040179.

4.

Eight novel loci implicate shared genetic etiology in multiple myeloma, AL amyloidosis, and monoclonal gammopathy of unknown significance.

Chattopadhyay S, Thomsen H, Weinhold N, Meziane I, Huhn S, da Silva Filho MI, Vodicka P, Vodickova L, Hoffmann P, Nöthen MM, Jöckel KH, Schmidt B, Landi S, Hajek R, Hallmans G, Pettersson-Kymmer U, Ohlsson C, Milani P, Merlini G, Rowcieno D, Hawkins P, Hegenbart U, Palladini G, Wechalekar A, Schönland SO, Houlston R, Goldschmidt H, Hemminki K, Försti A.

Leukemia. 2019 Nov 6. doi: 10.1038/s41375-019-0619-1. [Epub ahead of print] No abstract available.

PMID:
31695157
5.

The effects of different schedules of bortezomib, melphalan, and prednisone for patients with newly diagnosed multiple myeloma who are transplant ineligible: a matching-adjusted indirect comparison.

Mateos MV, San-Miguel J, Goldschmidt H, Sonneveld P, Dimopoulos MA, Heeg B, Hashim M, Deraedt W, Hu P, Lam A, He J.

Leuk Lymphoma. 2019 Nov 5:1-11. doi: 10.1080/10428194.2019.1675881. [Epub ahead of print]

PMID:
31686561
6.

Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9.

Schmidt AF, Holmes MV, Preiss D, Swerdlow DI, Denaxas S, Fatemifar G, Faraway R, Finan C, Valentine D, Fairhurst-Hunter Z, Hartwig FP, Horta BL, Hypponen E, Power C, Moldovan M, van Iperen E, Hovingh K, Demuth I, Norman K, Steinhagen-Thiessen E, Demuth J, Bertram L, Lill CM, Coassin S, Willeit J, Kiechl S, Willeit K, Mason D, Wright J, Morris R, Wanamethee G, Whincup P, Ben-Shlomo Y, McLachlan S, Price JF, Kivimaki M, Welch C, Sanchez-Galvez A, Marques-Vidal P, Nicolaides A, Panayiotou AG, Onland-Moret NC, van der Schouw YT, Matullo G, Fiorito G, Guarrera S, Sacerdote C, Wareham NJ, Langenberg C, Scott RA, Luan J, Bobak M, Malyutina S, Pająk A, Kubinova R, Tamosiunas A, Pikhart H, Grarup N, Pedersen O, Hansen T, Linneberg A, Jess T, Cooper J, Humphries SE, Brilliant M, Kitchner T, Hakonarson H, Carrell DS, McCarty CA, Lester KH, Larson EB, Crosslin DR, de Andrade M, Roden DM, Denny JC, Carty C, Hancock S, Attia J, Holliday E, Scott R, Schofield P, O'Donnell M, Yusuf S, Chong M, Pare G, van der Harst P, Said MA, Eppinga RN, Verweij N, Snieder H; Lifelines Cohort authors, Christen T, Mook-Kanamori DO; ICBP Consortium, Gustafsson S, Lind L, Ingelsson E, Pazoki R, Franco O, Hofman A, Uitterlinden A, Dehghan A, Teumer A, Baumeister S, Dörr M, Lerch MM, Völker U, Völzke H, Ward J, Pell JP, Meade T, Christophersen IE, Maitland-van der Zee AH, Baranova EV, Young R, Ford I, Campbell A, Padmanabhan S, Bots ML, Grobbee DE, Froguel P, Thuillier D, Roussel R, Bonnefond A, Cariou B, Smart M, Bao Y, Kumari M, Mahajan A, Hopewell JC, Seshadri S; METASTROKE Consortium of the ISGC, Dale C, Costa RPE, Ridker PM, Chasman DI, Reiner AP, Ritchie MD, Lange LA, Cornish AJ, Dobbins SE, Hemminki K, Kinnersley B, Sanson M, Labreche K, Simon M, Bondy M, Law P, Speedy H, Allan J, Li N, Went M, Weinhold N, Morgan G, Sonneveld P, Nilsson B, Goldschmidt H, Sud A, Engert A, Hansson M, Hemingway H, Asselbergs FW, Patel RS, Keating BJ, Sattar N, Houlston R, Casas JP, Hingorani AD.

BMC Cardiovasc Disord. 2019 Oct 29;19(1):240. doi: 10.1186/s12872-019-1187-z.

7.

Carfilzomib and dexamethasone versus eight cycles of bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma: an indirect comparison using data from the phase 3 ENDEAVOR and CASTOR trials.

Weisel K, Majer I, DeCosta L, Oriol A, Goldschmidt H, Ludwig H, Campioni M, Szabo Z, Dimopoulos M.

Leuk Lymphoma. 2019 Oct 22:1-10. doi: 10.1080/10428194.2019.1648806. [Epub ahead of print]

PMID:
31640435
8.

Health-related quality of life of carfilzomib- and daratumumab-based therapies in patients with relapsed/refractory multiple myeloma, based on German benefit assessment data.

Weisel K, Ludwig H, Rieth A, Lebioda A, Goldschmidt H.

Qual Life Res. 2019 Sep 24. doi: 10.1007/s11136-019-02307-5. [Epub ahead of print]

PMID:
31552577
9.

Cystic transformation of focal lesions after therapy is associated with remission but adverse outcome in myeloma.

Merz M, Hielscher T, Mai EK, Seckinger A, Hose D, Jauch A, Sauer S, Luntz S, Bertsch U, Raab MS, Neben K, Salwender H, Blau IW, Lindemann HW, Dürig J, Scheid C, Haenel M, Weisel K, Weber T, Delorme S, Goldschmidt H, Hillengass J.

Blood Cancer J. 2019 Aug 27;9(9):71. doi: 10.1038/s41408-019-0235-3. No abstract available.

10.

Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network.

Moreau P, Sonneveld P, Boccadoro M, Cook G, Mateos MV, Nahi H, Goldschmidt H, Dimopoulos MA, Lucio P, Bladé J, Delforge M, Hajek R, Ludwig H, Facon T, Miguel JFS, Einsele H.

Haematologica. 2019 Dec;104(12):2358-2360. doi: 10.3324/haematol.2019.224204. Epub 2019 Aug 22.

11.

Transcriptome-wide association study of multiple myeloma identifies candidate susceptibility genes.

Went M, Kinnersley B, Sud A, Johnson DC, Weinhold N, Försti A, van Duin M, Orlando G, Mitchell JS, Kuiper R, Walker BA, Gregory WM, Hoffmann P, Jackson GH, Nöthen MM, da Silva Filho MI, Thomsen H, Broyl A, Davies FE, Thorsteinsdottir U, Hansson M, Kaiser M, Sonneveld P, Goldschmidt H, Stefansson K, Hemminki K, Nilsson B, Morgan GJ, Houlston RS.

Hum Genomics. 2019 Aug 20;13(1):37. doi: 10.1186/s40246-019-0231-5.

12.

Salvage therapy versus upfront autologous stem cell transplantation in multiple myeloma patients with progressive disease after first-line induction therapy.

Blocka J, Hielscher T, Mueller-Tidow C, Goldschmidt H, Hillengass J.

Leuk Lymphoma. 2019 Aug 19:1-10. doi: 10.1080/10428194.2019.1646905. [Epub ahead of print]

PMID:
31423866
13.

Familial Cancer: How to Successfully Recruit Families for Germline Mutations Studies? Multiple Myeloma as an Example.

Blocka J, Durie BGM, Huhn S, Mueller-Tidow C, Försti A, Hemminki K, Goldschmidt H.

Clin Lymphoma Myeloma Leuk. 2019 Oct;19(10):635-644.e2. doi: 10.1016/j.clml.2019.06.012. Epub 2019 Jul 4.

PMID:
31377209
14.

Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial.

Mateos MV, Blacklock H, Schjesvold F, Oriol A, Simpson D, George A, Goldschmidt H, Larocca A, Chanan-Khan A, Sherbenou D, Avivi I, Benyamini N, Iida S, Matsumoto M, Suzuki K, Ribrag V, Usmani SZ, Jagannath S, Ocio EM, Rodriguez-Otero P, San Miguel J, Kher U, Farooqui M, Liao J, Marinello P, Lonial S; KEYNOTE-183 Investigators.

Lancet Haematol. 2019 Sep;6(9):e459-e469. doi: 10.1016/S2352-3026(19)30110-3. Epub 2019 Jul 18.

PMID:
31327687
15.

Prospective target assessment and multimodal prediction of survival for personalized and risk-adapted treatment strategies in multiple myeloma in the GMMG-MM5 multicenter trial.

Hose D, Beck S, Salwender H, Emde M, Bertsch U, Kunz C, Scheid C, Hänel M, Weisel K, Hielscher T, Raab MS, Goldschmidt H, Jauch A, Moreaux J, Seckinger A.

J Hematol Oncol. 2019 Jun 26;12(1):65. doi: 10.1186/s13045-019-0750-5.

16.

International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders.

Hillengass J, Usmani S, Rajkumar SV, Durie BGM, Mateos MV, Lonial S, Joao C, Anderson KC, García-Sanz R, Riva E, Du J, van de Donk N, Berdeja JG, Terpos E, Zamagni E, Kyle RA, San Miguel J, Goldschmidt H, Giralt S, Kumar S, Raje N, Ludwig H, Ocio E, Schots R, Einsele H, Schjesvold F, Chen WM, Abildgaard N, Lipe BC, Dytfeld D, Wirk BM, Drake M, Cavo M, Lahuerta JJ, Lentzsch S.

Lancet Oncol. 2019 Jun;20(6):e302-e312. doi: 10.1016/S1470-2045(19)30309-2. Review. Erratum in: Lancet Oncol. 2019 Jul;20(7):e346.

PMID:
31162104
17.

Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups.

Orlowski RZ, Moreau P, Niesvizky R, Ludwig H, Oriol A, Chng WJ, Goldschmidt H, Yang Z, Kimball AS, Dimopoulos M.

Clin Lymphoma Myeloma Leuk. 2019 Aug;19(8):522-530.e1. doi: 10.1016/j.clml.2019.04.018. Epub 2019 May 2.

18.

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.

Facon T, Kumar S, Plesner T, Orlowski RZ, Moreau P, Bahlis N, Basu S, Nahi H, Hulin C, Quach H, Goldschmidt H, O'Dwyer M, Perrot A, Venner CP, Weisel K, Mace JR, Raje N, Attal M, Tiab M, Macro M, Frenzel L, Leleu X, Ahmadi T, Chiu C, Wang J, Van Rampelbergh R, Uhlar CM, Kobos R, Qi M, Usmani SZ; MAIA Trial Investigators.

N Engl J Med. 2019 May 30;380(22):2104-2115. doi: 10.1056/NEJMoa1817249.

PMID:
31141632
19.

Germline Risk Contribution to Genomic Instability in Multiple Myeloma.

Janz S, Zhan F, Sun F, Cheng Y, Pisano M, Yang Y, Goldschmidt H, Hari P.

Front Genet. 2019 May 8;10:424. doi: 10.3389/fgene.2019.00424. eCollection 2019. Review.

20.

Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma.

Salwender H, Bertsch U, Weisel K, Duerig J, Kunz C, Benner A, Blau IW, Raab MS, Hillengass J, Hose D, Huhn S, Hundemer M, Andrulis M, Jauch A, Seidel-Glaetzer A, Lindemann HW, Hensel M, Fronhoffs S, Martens U, Hansen T, Wattad M, Graeven U, Munder M, Fenk R, Haenel M, Scheid C, Goldschmidt H.

BMC Cancer. 2019 May 28;19(1):504. doi: 10.1186/s12885-019-5600-x.

Supplemental Content

Loading ...
Support Center